An observational study in Milk Hypersensitivity, sponsored by Nutricia Nutrition Clinique. Completed at 1 site in France. Open to participants aged 8 Months and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-22.
Sponsored by Nutricia Nutrition Clinique (part of Danone) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Milk Hypersensitivity with a site in France — 1 open to participants now, 1 under way, none of them phase 3. Milk Hypersensitivity · France.
Among the 12 studies in Milk Hypersensitivity with a site in France, this one is the only one that started in 2021, is one of 2 observational ones, and was the 11th registered.
147 studies on the registry are indexed under Milk Hypersensitivity; 26 are open to participants now.
Browse Milk Hypersensitivity studies →1 of the 12 studies in Milk Hypersensitivity with a site in France is open now. Recruiting first, the newest first:
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement · Sites in France
Ages 18–65 · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 16 Milk Hypersensitivity studies recruiting now, 1 (6%) sets no upper age limit and 15 (94%) stop at 75 or younger; 15 take children under 18; 1 takes healthy volunteers.
This study: 8 Months and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2021.
This study's enrollment of 78 is below the median of 102 across 45 observational studies indexed under Milk Hypersensitivity.
Median enrollment 62 across the 10 interventional studies, 64 across the 2 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 10 most frequent:
This study is registered under Nutricia Nutrition Clinique, one of the names counted as Danone. Under that name alone:
Nutricia Nutrition Clinique is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Danone has 8 studies filed under Milk Hypersensitivity — fewer than ten, so there is no comparison to draw.
1 of the studies in Milk Hypersensitivity with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07239856Institut National de Recherche pour l'Agriculture, l'Alimentation et l'EnvironnementGoat vs. Cow Milk Digestive Tolerance | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Milk Hypersensitivity with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Nutricia wants to launch a real-life study, to see how the presence of prebiotics and probiotics in the boosted protein hydrolyzate can improve symptoms in the first weeks of use, and supplement the efficacy and safety data of the drug. formula, collected during clinical trials, with real life use. The target population will be children with a definite or suspected diagnosis of APLV, who have never taken a hypoallergenic formula, for whom the doctor decides to prescribe the Pepsicate Syneo formula, regardless of the clinical manifestation of the allergy. These children will be included before the age of 8 months and will be seen again 4 weeks after the prescription. The data from this real-life study will also better characterize the profile of infants taking Pepsicate Syneo. Finally, the perception of the formula by the parents will be collected.
Nutricia has developed an infant formula intended for children, APLV, from the class of foodstuffs intended for special medical purposes (DADFMS), called Pepticate Syneo. This hypoallergenic formula is based on high hydrolyzate of whey protein. It also contains:
In babies with a suspicion of non-IgE-mediated APLV, this symbiotic mixture (IcFOS, scGOS and B. Breve) allowed a modification of the fecal microbiota in 8 weeks, thus approaching the microbiota of breastfed infants of the same age, with an increase in Bifidobacteria and a decrease in Eubacterium rectale / Clostridium coccoides [Fox 2019].
All the available scientific data suggest an excellent tolerance of the Pepticate Syneo formula, and therapeutic efficacy on the manifestations of APLV, whether or not it is mediated by IgE, while ensuring the nutritional needs of children's growth. [Abrahamse-Berkeveld 2016, Giampietro 2001, Vandenplas 1993, Verwimp 1995].
The target population is made up of children under 8 months of age at inclusion, with a diagnosis or strong suspicion of APLV.
The study plans to include 78 patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
children under 8 months of age at inclusion, with a diagnosis or strong suspicion of APLV
Dietary Supplement: pepticate syneo
follow up of pepticate syneo for one month
effect on general condition
Assessment of the effect of the PEPTICATE SYNEO formula on the evolution of the general condition of a child with a PPLA using a 4-level Likert scale (worse / identical / improved / resolved)
Time frame: Day 28
Effect on evolution of allergic symptoms
Evaluation of the effect of the PEPTICATE SYNEO formula on the evolution of allergy symptoms using a 4-level Likert scale (worse / identical / improved / resolved)
Time frame: Day 28
effect on evolution of allergic symptoms according to Parents
Assessment of the effect of the PEPTICATE SYNEO formula on the evolution of allergy symptoms according to the parents using a 4-level Likert scale (worse / identical / improved / resolved)
Time frame: during one month
acceptability
Descriptive analysis of the acceptability of PEPTICATE SYNEO by parents using a questionnaire
Time frame: Day 28
Parent's quality of life
The quality of life of the parents (FAQL-PB score) will be measured by a Student test on paired samples.
Time frame: Day 28
CLINICAL PROFILE OF CHILDREN
Description of the clinical profile of the children at inclusion (Age, anthropometric data; growth; Food history, Risk factors for atopy..).
Time frame: Day 0
Consumption of the formula
Evaluation of the infant formula consumption of children before inclusion and during follow-up (lasting 28 days).
Time frame: during one month
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2021 to primary completion in May 2022, 11 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.